Sonendo acquires the portfolio of a dental company

0


Sonendo, Inc., a leading dental technology company and developer of the GentleWave® System, today announced the acquisition of all assets of FluidFile Ltd., an Israeli dental company.

FluidFile is a specialist endodontic company that has developed a range of options for alternative root canal treatments. The assets included in the transaction consist primarily of a patent portfolio of 24 granted patents and pending patent applications related to fluid motion technology in dental procedures. This transaction pursues Sonendo’s strategic goal of transforming the way root canals are treated. Sonendo’s intellectual property portfolio covering cleaning and disinfection in dentistry now includes more than 119 patents worldwide and supports Sonendo’s mission to improve the quality of life of patients by saving teeth and halting the progression of disease. tooth decay

“This acquisition is a significant investment in our business and our future. FluidFile patents complement Sonendo’s current patent portfolio and strengthen our already strong intellectual property position. We look forward to leveraging our intellectual property portfolio for unique product offerings that we believe will provide better and more efficient patient care and further adoption of our GentleWave technology, ”said Bjarne Bergheim, President and Chief Executive Officer of Sonendo.

Sonendo’s GentleWave procedure represents the next wave in the evolution of endodontic technology and can improve the patient experience. The GentleWave procedure is designed to provide more thorough cleaning and disinfection of the entire root canal system, even in microscopic places where bacteria can hide, and leave more of the tooth structure intact.1.2. Most GentleWave procedures can be performed in one visit, and patients generally have found the procedure comfortable.3. In addition, the GentleWave system is designed to generate virtually no aerosolized material in the air during normal use.4, which has become a significant issue for clinicians and patients during the COVID-19 pandemic due to increased sensitivity to concerns associated with aerosol cross-contamination. The procedural instruments for the GentleWave System are also pre-sterilized and single-use, further minimizing the risk of patient-to-patient exposure.

About Sonendo® and TDO® Software

Sonendo, Inc. is a privately-held, commercial-stage medical technology company focused on protecting teeth against dental decay, the world’s most common chronic disease. The GentleWave System is an innovative technology platform designed to treat tooth decay by cleaning and disinfecting microscopic spaces inside teeth without the need to remove tooth structure 1.2. The system uses our proprietary mechanism of action, which combines procedural fluid optimization, broad-spectrum acoustic energy, and advanced fluid dynamics, to debride and disinfect deep regions of the complex root canal system during a less invasive procedure that preserves tooth structure. 1,2,3. The clinical advantages of our GentleWave System over conventional root canal treatment methods include improved clinical outcomes, such as superior cleaning independent of root canal complexity and tooth anatomy, high healing rates and rapid and minimal or no postoperative pain. 1.3. In addition to clinical benefits, the GentleWave system can improve the workflow and economy of dental practices. Sonendo is also the parent company of TDO Software, the developer of widely used endodontic practice management software solutions designed to simplify practice workflow. The TDO software seamlessly integrates practice management, imaging, referral reports, CBCT imaging and offers integrated communication with the GentleWave system.

For more information about Sonendo, visit sonendo.com. For more information on TDO, visit tdo4endo.com.

THE REFERENCES

1Sigurdsson A et al. (2016) J Endod. 42: 1040-48. 2Molina B et al. (2015) J Endod. 41: 1701-05. 3Sigurdsson et al. J Endod 2018; 44 (3): 510-517. 4Data archived at Sonendo; internal test report # TR20-002.

FORWARD-LOOKING STATEMENTS

This announcement contains forward-looking statements based on the beliefs, assumptions and expectations of management and on information currently available to management. All statements that deal with events or developments that we expect or anticipate will occur in the future are forward-looking statements, including, but not limited to our expectations about the timing and progress of research and development activities. Management believes these forward-looking statements are reasonable as they are made. However, you should not place undue reliance on forward-looking statements because they speak only as of the date they are made. Sonendo assumes no obligation to publicly update or revise forward-looking statements, whether based on new information, future events or otherwise. Actual results, developments or events could differ materially from those disclosed in forward-looking statements.


Leave A Reply

Your email address will not be published.